Category - Developments

Developments

Kazia reveals compelling data on nuclear PD-L1 degrader NDL2

Kazia Therapeutics (NASDAQ: KZIA) has announced compelling preclinical and translational data supporting the development of NDL2, a potentially first-in-class protein degrader designed to selectively eliminate nuclear...

January 30, 2026

Developments

Immunotherapy review highlights Faron’s bexmarilimab in immune-resistant cancer

Faron Pharmaceuticals (AIM: FARN; First North: FARON) has announced the publication of a comprehensive review article in the peer-reviewed journal Immunotherapy detailing the potential of the company’s lead candidate...

January 29, 2026

Developments

OSE expands lusvertikimab into new immune-mediated indications

OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) has announced that it has selected chronic pouchitis and hidradenitis suppurativa (HS) as new key indications for lusvertikimab, a potential first-in-class IL-7R...

January 29, 2026

Developments

FDA certifies LSL’s ophthalmic ointment manufacturing for U.S. market

LSL Pharma (TSXV: LSL) has announced that the FDA has certified the ophthalmic ointment manufacturing operations of its subsidiary, Steri-Med Pharma, clearing the company to commercialize ophthalmic ointment products in...

January 28, 2026

Developments

FDA grants En Carta BDD for EC Pocket Lyme test

Closely held En Carta Diagnostics has announced that its EC Pocket Lyme test for the early detection of Borrelia bacteria—the cause of Lyme disease—has received Breakthrough Design Designation (BDD) from the FDA. EC...

January 28, 2026

Developments

Omeros launches first commercial sales of YARTEMLEA for TA-TMA

Omeros (NASDAQ: OMER) has announced that it has completed its first commercial shipments of YARTEMLEA to distributors for the treatment of adult and pediatric patients with stem cell transplant-associated thrombotic...

January 27, 2026

Developments

Ernexa chosen as one of ten for JETRO acceleration program

Ernexa Therapeutics (NASDAQ: ERNA) has announced it was selected as one of only ten global companies to participate in the prestigious Japan Entry Acceleration Program (JEAP) by the Japan External Trade Organization...

January 27, 2026

Developments

Pluri completes first phase of placenta-derived biomaterials program

Pluri (NASDAQ, TASE: PLUR) has announced the completion of the first phase of its program with closely held Resbiomed Technologies OOD, a European biotechnology company developing extracellular-matrix- based...

January 22, 2026

Developments

Hoth reports positive interim results from trial of HT-001 in cancer patients

Hoth Therapeutics (NASDAQ: HOTH) has announced 100% clinical response and approximately 50% reduction in disease severity in the open-label pharmacokinetic (PK) cohort of its ongoing CLEER-001 clinical trial evaluating...

January 22, 2026

Developments

Actuate to advance Elraglusib tablet to Phase 1/2 program in refractory cancers

Actuate Therapeutics (NASDAQ: ACTU) has announced plans to initiate a Phase 1/2 clinical program evaluating the oral tablet dosage form of elraglusib in patients with advanced cancer. According to Actuate, the goal of...

January 21, 2026

Category - Developments

Subscribe